Hepatic decompensation was not prevented by
lamivudine compared to placebo or entecavir compared to
lamivudine in three underpowered trials.
Hepatocellular carcinoma was not prevented in four studies with inadequate size and duration. In one RCT, analysis that adjusted for country, sex, baseline ALT level, Child-Pugh score, and Ishak fibrosis score and excluded five individuals who developed HCC within the first year of the study found a borderline significant effect of lamivudine.